Articles Related to alcohol consumption
The Contribution of Alcohol Consumption to Overall Cancer Incidence in the Western World: A Meta-Analysis
The effect of alcohol consumption on overall cancer incidence is not clear. The aim of the paper is to estimate the impact of alcohol consumption on risk distribution of the 20 most common cancer types among men and women in the Western world. A meta-analysis of relative risks for the 20 most common cancer types potentially associated with alcohol consumption in the Western world was conducted based on the most recent cancer specific meta-analyses. Cancer risks were compared between men and women applying a sigmoidal dose response model. Drinking 2.5-14.9 g alcohol/day was associated with a small decrease in overall cancer incidence: 0.977 for men and 0.974 for women; followed by a small increase in the 15-29.9 g/day category: 1.029 for men and 1.077 for women. Further increases were observed in the 30-60 g/day category indicating a 5 and 10% increase in overall cancer risk for men and women, respectively. Women appeared to be more sensitive: the alcohol consumption level to acquire overall risk increase is 22 g/day for women and 46 g/day for men.
The 2015 Dutch Food-Based Dietary Guidelines on Alcohol Consumption - A Critical Review
Background: Recently the Dutch Health Council has issued a revised alcohol guideline stating: Do not drink alcohol, or if any only drink one glass daily. The current guidelines are intended to obtain the lowest disease burden of the most burdensome diseases in The Netherlands. The current paper aims to estimate the overall impact of alcohol consumption on these diseases.
Bioequivalence Study of Two Oral-Capsule Formulations of Pregabalin 300 mg in Healthy Mexican Adult Volunteers
Pregabalin is a ligand for the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It has anticonvulsant, analgesic, and anxiolytic activity. The bioequivalence of a test formulation was evaluated with respect to its corresponding reference drug formulation of oral pregabalin 300 mg, administered as a capsule. This randomized-sequence, single-dose, single-blind, two-period crossover design under fasting conditions was done on 25 healthy Mexican adult subjects including both genders. There was a seven-day washout period.
Esophageal Cancer and Bisphosphonates
At the beginning of 2009, Dianne Wysowski of the US Food and Drug Administration summarized 23 reports of esophageal1 cancer following alendronate use. Wysowski also noted that there had been 31 cases following alendronate use in Europe and Japan and ten cases in which other bisphosphonates had been reported as concomitant or suspect treatment.